Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03833921 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

A Phase 2 study of Prostate Cancer and Prostate Cancer Metastatic, sponsored by Martha Mims.

Recruiting
Registry status
Phase 2
Development phase
130
Enrollment target
3
Study locations

NCT03833921: Recruiting Phase 2 study of Prostate Cancer and Prostate Cancer Metastatic, sponsored by Martha Mims.

NCT03833921 is a Phase 2 study of Prostate Cancer and Prostate Cancer Metastatic that is actively recruiting participants, run by Martha Mims. The registered enrollment target is 130 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03833921, a Phase 2 study of Prostate Cancer and Prostate Cancer Metastatic, is actively recruiting participants, sponsored by Martha Mims.

RECRUITING
Registry status
Phase 2
Development phase
130 participants
Enrollment target
3
Study locations

Study Summary

The investigators are conducting this study with men that have prostate cancer and are getting standard of care treatment with the drugs abiraterone acetate and prednisone. The study will follow men with prostate cancer from initiation of participation in the study and for up to 10 years. The reason for the study is that researchers think that there may be a connection between the race and ethnicity of men with prostate cancer and how well the standard treatments work for the participants.

Primary Outcome

The proportion of subjects with PSA levels less than 4 ng/ml at the given time point.

Interventions

  • DRUG Prednisone
  • DRUG Abiraterone Acetate

Study Locations (3)

Texas

  • Ben Taub General Hospital - Houston
  • Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine - Houston
  • Michael E. DeBakey Veterans Affairs Medical Center - Houston

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2019-05-23
Est. Completion 2038-04
Phase Phase 2
Martha Mims

1 total trials

What NCT03833921 shows while recruiting

NCT03833921 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% lower).

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Prednisone is the first listed.

NCT03833921 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03833921 about?

NCT03833921 is a clinical study titled "Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer". The investigators are conducting this study with men that have prostate cancer and are getting standard of care treatment with the drugs abiraterone acetate and prednisone. The study will follow men with prostate cancer from initiation of participation in the study and for up to 10 years. The reason...

What is the current status of trial NCT03833921?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2019-05-23. Estimated completion is 2038-04.

What conditions does trial NCT03833921 study?

This clinical trial studies the following conditions: Prostate Cancer, Prostate Cancer Metastatic.

What interventions are being tested in trial NCT03833921?

The interventions under investigation include: Prednisone (DRUG), Abiraterone Acetate (DRUG).

Who is sponsoring clinical trial NCT03833921?

This trial is sponsored by Martha Mims, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03833921 being conducted?

This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03833921's enrollment target sits among peer trials

130 292nd of 735 higher than 442 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492036 · 130 participants

    Long-Term Follow-Up of Recipient of Gene Transfer Research

  • NCT01631617 · 130 participants · Phase 2

    Effects of Treatments on Atopic Dermatitis

  • NCT02368041 · 130 participants

    Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure

  • NCT02604277 · 130 participants · NA

    Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03833921, the US trial registry maintained by the National Library of Medicine. NCT03833921 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.